Artelo Biosciences (ARTL) Investor presentation summary

Corporate highlights

• Advancing a platform of lipid signaling modulation drug candidates for pain, cancer, anxiety, and depression.

• Focused on billion-dollar markets with a robust patent estate and experienced leadership.

Pipeline overview

• ART27.13: Dual cannabinoid receptor agonist for cancer-related anorexia and cachexia, in Phase 2.

• ART26.12: FABP5 inhibitor targeting chemotherapy-induced peripheral neuropathy and various cancers, in Phase 1.

• ART12.11: CBD:TMP cocrystal for anxiety and depression, in late preclinical development.

Clinical and preclinical results

• ART27.13 showed dose-dependent weight gain and muscle preservation in preclinical and clinical studies, with 64% of patients experiencing weight stabilization or gain in Phase 1.

• CARES Phase 2 interim data: ART27.13 led to an average 6% weight increase at highest dose versus 5% decrease with placebo; increased patient activity observed.

• ART26.12 demonstrated reversal of neuropathic pain in multiple animal models and showed an excellent safety profile in Phase 1 SAD/FE study.

• ART12.11 exhibited superior anxiolytic and antidepressant effects in preclinical models compared to CBD alone.